Guggenheim initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $41 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- RBC sees Makary interview as potentially positive for biotech stocks
- Edgewise Therapeutics: A Promising Future Amidst Initial Concerns
- Biotech Alert: Searches spiking for these stocks today
- Edgewise downgraded yesterday at Scotiabank after CIRRUS-HCM readout
- Edgewise downside move a buying opportunity, says RBC Capital